[ad_1] STOCKHOLM, Dec. 5, 2024 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) […]
Tag: BioArctic
Leqembi® launched in South Korea
[ad_1] STOCKHOLM, Nov. 28, 2024 /PRNewswire/ – BioArctic AB’s (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced today that Leqembi® (generic name: lecanemab) has been launched in South Korea. Leqembi received approval in South Korea […]
Leqembi® launched in South Korea
[ad_1] STOCKHOLM, Nov. 27, 2024 /PRNewswire/ – BioArctic AB’s (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced today that Leqembi® (generic name: lecanemab) has been launched in South Korea. Leqembi received approval in South Korea […]
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024
[ad_1] STOCKHOLM, Nov. 8, 2024 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs from April 2024 through March […]
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024
[ad_1] STOCKHOLM, Nov. 7, 2024 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs from April 2024 through March […]
